This finding is especially relevant in light of a recent meta-analysis of the TCGA cohort, which revealed a significant focal loss of CpG methylation throughout the genomes of AML patients harboring DNMT3A mutations.[9] Mean beta values were also further reduced in DNMT3AR882 compared to DNMT3Anon-R882 samples, supporting in vitro evidence that R882 mutations impair methyltransferase activity more severely than mutations at other residues. This evidence concerns the gene DNMT3A and acute myeloid leukemia.